Browse studies

Find your next paid study

135 recruiting studies matching your filters

A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

The purpose of Part 1 (Dose Escalation) of the study is to assess how safe and tolerable JNJ-95804306 is and to find out the most suitable dose (recommended ph…

Hematologic Neoplasms

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Janssen Research & Development, LLCNCT07572006

Phase 2

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended…

Hematological Malignancies

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Janssen Research & Development, LLCNCT04634552

Phase 1

A Pilot Trial of Abatacept Based Graft-Versus-Host Disease Prophylaxis Following Omidubicel Hematopoietic Cell Transplantation

This study is a single-center, non-randomized, single-arm pilot trial of omidubicel hematopoietic stem cell transplantation (HCT) for hematologic malignancies …

Hematologic Malignancy

Estimated

~$150 – $3,000

Actual pay is set by the research site.

Duke UniversityNCT06731504

Phase 1

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer…

HIVHematologic Malignancies

Estimated

~$500 – $6,750

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05470491

Longitudinal Studies of Patients and Families With Familial Platelet Disorders With Associated Myeloid Malignancy (FPDMM) Caused by RUNX1 Germline Variants or FPDMM-Like Conditions

Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant …

Inherited Hematological DiseasesRare DiseasesFPDMM

Estimated

~$10 – $675

Actual pay is set by the research site.

National Human Genome Research Institute (NHGRI)NCT03854318

Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls

This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study …

Healthy SubjectHematologic and Lymphocytic DisorderHematopoietic and Lymphoid Cell Neoplasm+2 more

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Southern CaliforniaNCT03207854

Response to Influenza Vaccination in Pediatric Oncology Patients

Influenza infection occurring during oncologic treatment or following hematopoietic cell transplantation (HCT) is associated with increased risk of morbidity i…

Hematologic MalignancyPediatric CancerTransplant-Related Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT05384288

Observational

Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities

Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer r…

Breast CancerGastrointestinal CancerHematologic Cancer

Estimated

~$10 – $750

Actual pay is set by the research site.

Baylor College of MedicineNCT05323409

Phase 1

A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN)

Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this i…

Systemic Mastocytosis With an Associated Hematologic Neoplasm

Estimated

~$150 – $3,000

Actual pay is set by the research site.

H. Lee Moffitt Cancer Center and Research InstituteNCT06327685

Phase 1

A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic Malignancies and High-Risk Newly Diagnosed AML

SLS009 (formerly GFH009) is a potent and highly selective CDK9 inhibitor. In this study the safety, tolerability, and antitumor activity of single agent SLS009…

Hematologic Malignancies

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Sellas Life Sciences GroupNCT04588922

Phase 1

Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)

The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies un…

Hematologic MalignancyGvHDGVHD,Acute+8 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Tr1X, Inc.NCT06462365

An Observational Long-Term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy

This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sp…

Lymphoma, Non-HodgkinRelapsed Non-Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma+7 more

Estimated

Pay not disclosed — ask the coordinator

Caribou Biosciences, Inc.NCT05332054